[go: up one dir, main page]

PE20191236A1 - Compuestos de pirazolopirimidina y metodos de uso de los mismos - Google Patents

Compuestos de pirazolopirimidina y metodos de uso de los mismos

Info

Publication number
PE20191236A1
PE20191236A1 PE2019001227A PE2019001227A PE20191236A1 PE 20191236 A1 PE20191236 A1 PE 20191236A1 PE 2019001227 A PE2019001227 A PE 2019001227A PE 2019001227 A PE2019001227 A PE 2019001227A PE 20191236 A1 PE20191236 A1 PE 20191236A1
Authority
PE
Peru
Prior art keywords
methods
cyano
halogen
compounds
group
Prior art date
Application number
PE2019001227A
Other languages
English (en)
Inventor
Mark Zak
Guiling Zhao
Paul Gibbons
Wei Li
Yun-Xing Cheng
Po-Wai Yuen
Limin Cheng
F Anthony Romero
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20191236A1 publication Critical patent/PE20191236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referido a un compuesto de formula general (IA), o una sal farmaceuticamente aceptable, en donde: A es un anillo condensado seleccionado entre el grupo que consiste en un grupo aromatico de 6 miembros, un grupo heterociclico de 5 o 6 miembros, entre otros; R es H, halogeno, ciano, entre otros; R0 es H, halogeno, ciano, alquilo C1-C3, entre otros; R1 es H, alquenilo C2-C6, entre otros. Un compuesto preferido es N-[3-[3-(difluorometoxi)-2-naftil]-1H-pirazol-4-il]pirazolo[1,5-a]pirimidin-3-carboxamida. Estos compuestos son inhibidores de molecula pequena de una Janus cinasa, tal como JAK1. Tambien se refiere a metodos de preparacion de los mismos, sus compuestos intermedios y su uso en el tratamiento de una enfermedad inflamatoria como el asma.
PE2019001227A 2016-12-29 2017-12-22 Compuestos de pirazolopirimidina y metodos de uso de los mismos PE20191236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016112932 2016-12-29

Publications (1)

Publication Number Publication Date
PE20191236A1 true PE20191236A1 (es) 2019-09-11

Family

ID=61094385

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001227A PE20191236A1 (es) 2016-12-29 2017-12-22 Compuestos de pirazolopirimidina y metodos de uso de los mismos

Country Status (19)

Country Link
US (1) US11155557B2 (es)
EP (1) EP3562809B1 (es)
JP (1) JP6900491B2 (es)
KR (1) KR20190100337A (es)
CN (1) CN110114343B (es)
AU (1) AU2017385543A1 (es)
BR (1) BR112019013287A2 (es)
CA (1) CA3046435A1 (es)
CL (1) CL2019001694A1 (es)
CO (1) CO2019006220A2 (es)
CR (1) CR20190310A (es)
IL (1) IL267671A (es)
MA (1) MA47167A (es)
MX (1) MX2019007339A (es)
PE (1) PE20191236A1 (es)
PH (1) PH12019501022A1 (es)
RU (1) RU2019123319A (es)
UA (1) UA122851C2 (es)
WO (1) WO2018122212A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191236A1 (es) 2016-12-29 2019-09-11 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos
TW201902896A (zh) 2017-05-22 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療化合物及組合物及其使用方法
JP7339263B2 (ja) * 2018-01-15 2023-09-05 エフ． ホフマン－ラ ロシュ アーゲー Ｊａｋ阻害剤としてのピラゾロピリミジン化合物
WO2020257145A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
EP3986899A1 (en) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
WO2020257142A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AR130426A1 (es) * 2022-09-09 2024-12-04 Chiesi Farm Spa Derivados heterocíclicos como inhibidores de janus quinasa
AU2023336560A1 (en) * 2022-09-09 2025-04-17 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AU2015261812B2 (en) 2014-05-23 2019-11-21 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
CN108473501B (zh) 2016-02-18 2021-07-16 豪夫迈·罗氏有限公司 治疗化合物、其组合物及使用方法
AU2017289014B2 (en) 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
PE20191236A1 (es) 2016-12-29 2019-09-11 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos

Also Published As

Publication number Publication date
US20190345165A1 (en) 2019-11-14
MA47167A (fr) 2019-11-06
BR112019013287A2 (pt) 2019-12-24
WO2018122212A1 (en) 2018-07-05
CO2019006220A2 (es) 2019-06-28
RU2019123319A3 (es) 2021-02-01
EP3562809B1 (en) 2021-06-09
CL2019001694A1 (es) 2019-11-22
CA3046435A1 (en) 2018-07-05
IL267671A (en) 2019-08-29
RU2019123319A (ru) 2021-02-01
EP3562809A1 (en) 2019-11-06
KR20190100337A (ko) 2019-08-28
PH12019501022A1 (en) 2019-12-16
US11155557B2 (en) 2021-10-26
UA122851C2 (uk) 2021-01-06
MX2019007339A (es) 2019-09-06
CN110114343A (zh) 2019-08-09
AU2017385543A1 (en) 2019-05-23
CN110114343B (zh) 2022-09-06
JP6900491B2 (ja) 2021-07-07
JP2020503339A (ja) 2020-01-30
CR20190310A (es) 2019-08-21

Similar Documents

Publication Publication Date Title
PE20191236A1 (es) Compuestos de pirazolopirimidina y metodos de uso de los mismos
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
JOP20190143A1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
EA202092441A1 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
PE20190339A1 (es) 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
PE20210658A1 (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat)
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
AR091285A1 (es) Inhibidores de bromodominio y sus usos
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
PE20051089A1 (es) Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
PH12020550143A1 (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
EA201691934A1 (ru) Замещенные 4,5,6,7-тетрагидро-пиразоло[1,5-альфа]пиримидиновые производные и 2,3-дигидро-1h-имидазо[1,2-бета]пиразольные производные в качестве ингибиторов ros1